Phase 1 Study of a Second Group Psilocybin Therapy Experience for Cancer Patients

Data Sheet 1_A is a PDF document containing results from a single-arm Phase 1 clinical trial. The study, authored by Anthony L. Back and uploaded to figshare in April 2026, assessed the safety and preliminary efficacy of a second group retreat psilocybin therapy experience for 13 partial responders with metastatic cancer. It reports on adverse events, changes in Hospital Anxiety and Depression Scale (HADS) scores, and mystical experience questionnaire results over a 24-week follow-up.

Use Cases

• Analyzing safety profiles based on reported adverse events like transient hypertension, nausea, and headache.
• Modeling treatment efficacy trajectories based on HADS score changes from baseline to 24-week follow-up.
• Studying the relationship between mystical experience scores (MEQ) and clinical outcomes.
• Investigating the impact of protocol modifications, such as a higher initial dose and optional booster, on participant response.
• Examining longitudinal changes in social support, group cohesion, and social identification scores.

Strengths

• Includes specific numerical results for a cohort of 13 participants, with mean HADS scores decreasing from 15.08 to 9.00.
• Provides detailed protocol information, including dose modifications (35 mg initial, optional 10 mg booster) and session structure.
• Reports longitudinal data with measurements at baseline, Day +8, and 24-week follow-up.
• Contains quantified outcomes for mystical experiences (MEQ ≥ 60% increased from 38% to 77%) and challenging experiences.

Limitations

• The dataset is a 910.7 KB PDF report; the underlying raw tabular or time-series data is not directly accessible.
• Row count and column-level documentation for any underlying data are unknown, limiting suitability assessment.
• The study sample is small (n=13) and specific to partial responders with metastatic cancer from a prior study.

Provenance

Source

figshare, authored by Anthony L. Back.

Collection Method

Single-arm Phase 1 clinical trial with a defined intervention protocol.

Time Range

Study period and 24-week follow-up; specific dates not provided.

Freshness

Last updated 2026-04-14 13:58:06

Geography

Not specified in the provided description.